Articles by Ariel DeMaio
This article reviews the proposed mechanisms of action of venetoclax in AML and the potential future of venetoclax in AML.
This phase II study enrolled 34 adult patients with intermediate- to high-risk myelofibrosis.
The chemotherapy-free approach of blinatumomab monotherapy could represent a promising therapy for older adults.
Drs. Short and Webster, discussed their differing views of the current position of transplantation in the treatment of ALL.
Two adults who received infusions of anti-CD19 CAR T-cell therapy tisagenlecleucel were in remission at nine and ten years.
Tisagenlecleucel was well-tolerated with manageable toxicity in patients with primary central nervous system lymphoma.
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Peripheral T-cell lymphomas represent about 10% to 15% of all non-Hodgkin lymphomas.
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Ibrutinib and venetoclax demonstrated superior MRD responses in older/unfit patients with previously untreated CLL.
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the treatment ...
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.